{"id":"W2896825577","doi":"10.1007/s10637-018-0680-z","title":"Canadian Cancer Trials Group (CCTG) IND215: A phase Ib study of Selumetinib in patients with untreated advanced or metastatic NSCLC who are receiving standard chemotherapy regimens","year":2018,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":false,"ca_institutions":"Hamilton Health Sciences; University of Toronto; Queen's University; BC Cancer Agency; Princess Margaret Cancer Centre; Ottawa Hospital; Juravinski Cancer Centre","funders":"Canadian Cancer Society Research Institute","keywords":"Selumetinib; Medicine; Carboplatin; Pemetrexed; Cohort; Internal medicine; Adverse effect; Chemotherapy; Tolerability; Neutropenia; Oncology; Cisplatin; Cancer; Gastroenterology; KRAS","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001757423,0.001691723,0.002502689,0.0004942524,0.001035528,0.001379309,0.001284011,0.001759328,0.00544345],"category_scores_gemma":[0.001313793,0.0005578931,0.002116399,0.0008685096,0.001323456,0.0007594013,0.000446602,0.00431151,0.0009766588],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.005618465,"about_ca_system_score_gemma":0.00884595,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.06218669,"about_ca_topic_score_gemma":0.2526982,"domain_scores_codex":[0.999398,0.0002149166,0.00001946633,0.00008074636,0.00009245466,0.0001945085],"domain_scores_gemma":[0.9992873,0.00007886247,0.00009074894,0.00003593271,0.00005616794,0.0004509747],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.7746794,0.0292478,0.01267557,0.001422407,0.004060792,0.0003507344,0.0003141836,0.003344878,0.01374143,0.0007866134,0.03637827,0.1229979],"study_design_scores_gemma":[0.8304784,0.1212036,0.02730473,0.00008578666,0.001703351,0.0002418044,0.0001242932,0.001219242,0.001495904,0.0003733724,0.01568727,0.00008224186],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.957693,0.00946999,0.0003879301,0.004764838,0.0006222303,0.004319299,0.01011809,0.0002230898,0.01240157],"genre_scores_gemma":[0.9593542,0.007225804,0.002184856,0.004969534,0.0003702523,0.00265984,0.0146398,0.00007324479,0.008522636],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.06218669,"threshold_uncertainty_score":0.1236494,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03154237553643747,"score_gpt":0.3657243787929642,"score_spread":0.3341820032565267,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}